{"id":23493,"date":"2026-03-03T01:15:25","date_gmt":"2026-03-03T01:15:25","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/23493\/"},"modified":"2026-03-03T01:15:25","modified_gmt":"2026-03-03T01:15:25","slug":"nestles-strategy-for-glp-1-innovation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/23493\/","title":{"rendered":"Nestl\u00e9’s strategy for GLP-1 innovation"},"content":{"rendered":"

How is Nestl\u00e9 responding to GLP-1 disruption? SummaryGLP-1 drugs are reshaping food demand through appetite suppression trendsNestl\u00e9 is first major CPG to launch products for GLP-1 usersPartnerships with UC Davis and ACU aim to accelerate nutrition innovationFocus areas include weight management, women\u2019s health and healthy longevityNestl\u00e9\u2019s Vital Pursuit meals and microgel drinks target satiety and control<\/p>\n

GLP-1 drugs are predicted to completely disrupt food and beverage. While some CPGs hold back, waiting to see how suppressed appetites and curbed cravings will hit sales, others are leaning into the challenge.<\/p>\n

Nestl\u00e9 is among the latter. As the first CPG giant out of the blocks to specifically cater to GLP-1 users, the multinational wants to follow up with more products \u2013 not all of which will come from in-house innovation.<\/p>\n

Wanted: \u2018Disruptive ideas\u2019 for weight management<\/p>\n

Although much of Nestl\u00e9\u2019s innovation is developed by its own experts, the company acknowledges it can\u2019t do it all. A new partnership between the University of California, Davis and Nestl\u00e9 Health Science aims to bolster innovation across nutrition and health, and start-up development.<\/p>\n

Another in the southern hemisphere, with Australian Catholic University in Melbourne, will establish an incubator programme for growth areas like weight management. <\/p>\n

\u201cOur focus is on supporting people on weight-loss journeys with the right nutrition,\u201d a Nestl\u00e9 spokesperson explains. \u201cThat could mean, for example, protein, biotics, and collagen both during the weight-loss period and afterwards during the maintenance period.\u201d<\/p>\n

Both initiatives are still in their \u201cearly stages\u201d, but Nestl\u00e9 has confirmed they\u2019ll also be focused on two other key areas for the business: women\u2019s health and healthy longevity.<\/p>\n

Nestl\u00e9 says goals align with its R&D Accelerator programme, which supports work on \u201cdisruptive ideas\u201d grounded in cutting-edge science, technological advances, and evolving consumer needs.<\/p>\n

Weight management a \u2018growth platform\u2019 for Nestl\u00e9<\/p>\n

Alongside women\u2019s health and healthy longevity, Nestl\u00e9 has identified weight management as a \u201cgrowth platform\u201d for the company. That\u2019s perhaps unsurprising given the estimated number of consumers taking GLP-1 drugs like Wegovy, Ozempic, or Mounjaro. <\/p>\n

In the US alone, it\u2019s thought 41 million people have used them. With weekly pills and monthly injections in development, and some GLP-1 drugs expected to soon go off patent, uptake could surge. And in a flash, demand for products that support weight management could skyrocket. <\/p>\n

Also read \u2192 How big is the GLP-1 wave going to get, really?<\/a><\/p>\n

For Nestl\u00e9, any new innovations to come out of the academic partnerships would build on its growing portfolio of weight management products. The company is selling high protein, high fibre, portion-controlled ready meals for GLP-1 users via its Vital Pursuit brand, and has developed its own whey protein microgel technology to manage blood sugar levels and appetite control in beverages \u2013 like its Boost Pre-Meal Hunger Support products.<\/p>\n

We\u2019re told more innovation is on the horizon, so watch this space.<\/p>\n

\"WeightWeight Management Digital Summit 2025 (William Reed)Want to learn more about weight management in the GLP-1 era?<\/p>\n

How is the food industry responding to the rise of GLP-1s like Wegovy or Mounjaro?<\/p>\n

From reformulation to portion control, appetite suppression to satiety science – the GLP-1 revolution is reshaping how we think about food innovation and weight management.<\/p>\n

Join us at our free digital summit to hear from leading experts, brands and researchers tackling the big questions:<\/p>\n

What role can food play in supporting GLP-1 users?How are consumer needs and expectations evolving?What are the opportunities for innovation?<\/p>\n

Weight Management: Food Innovation in the GLP-1 Era will be broadcast 13 & 19 November 2025.<\/p>\n

A detailed agenda and free registration is available here<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"How is Nestl\u00e9 responding to GLP-1 disruption? SummaryGLP-1 drugs are reshaping food demand through appetite suppression trendsNestl\u00e9 is…\n","protected":false},"author":2,"featured_media":23494,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[126],"tags":[1716,14970,14971,14972,11372,14973,14974,14975,14976,14977,14978,1002,12830,4128,14979,14980,14981,14982,1053,14983,8272,14984,14985,13404,199,2403,14986,14987,14988,14989,1904],"class_list":["post-23493","post","type-post","status-publish","format-standard","has-post-thumbnail","category-nestle","tag-background","tag-blood-glucose","tag-blood-sugar","tag-blue-pen","tag-clinic","tag-colorful","tag-daily-injection","tag-device","tag-diabetic","tag-diabetic-care","tag-endocrinology","tag-health","tag-health-care","tag-healthcare","tag-injection","tag-injector","tag-insulin-injection","tag-insulin-pen","tag-lifestyle","tag-medical","tag-medical-device","tag-medical-tool","tag-medicament","tag-medication","tag-nestle","tag-object","tag-ozempic","tag-pink-and-blue","tag-sugar","tag-treatment","tag-weight-loss"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=23493"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/23493\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/23494"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=23493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=23493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=23493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}